Rocket Pharmaceuticals holders convert 6.25% notes ahead of redemption

By Marisa Wong

Los Angeles, April 27 – Holders of about $38.35 million of Rocket Pharmaceuticals, Inc.’s 6.25% convertible senior notes due 2022 converted the notes into about 1.3 million shares of the company’s common stock and cash in lieu of fractional shares, according to an 8-K filing with the Securities and Exchange Commission.

The company had issued a notice of full redemption on March 26 for its roughly $38.35 million outstanding 6.25% notes.

The conversions took place prior to April 26.

Based in New York, Rocket Pharmaceuticals is a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.